These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 31911131)

  • 1. Advances in detecting and reducing off-target effects generated by CRISPR-mediated genome editing.
    Li J; Hong S; Chen W; Zuo E; Yang H
    J Genet Genomics; 2019 Nov; 46(11):513-521. PubMed ID: 31911131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxycycline-Dependent Self-Inactivation of CRISPR-Cas9 to Temporally Regulate On- and Off-Target Editing.
    Kelkar A; Zhu Y; Groth T; Stolfa G; Stablewski AB; Singhi N; Nemeth M; Neelamegham S
    Mol Ther; 2020 Jan; 28(1):29-41. PubMed ID: 31601489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR Guide RNA Design Guidelines for Efficient Genome Editing.
    Schindele P; Wolter F; Puchta H
    Methods Mol Biol; 2020; 2166():331-342. PubMed ID: 32710418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
    Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
    Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening of CRISPR/Cas base editors to target the AMD high-risk Y402H complement factor H variant.
    Tran MTN; Khalid MKNM; Pébay A; Cook AL; Liang HH; Wong RCB; Craig JE; Liu GS; Hung SS; Hewitt AW
    Mol Vis; 2019; 25():174-182. PubMed ID: 30996586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR-gRNA Design.
    Pallarès Masmitjà M; Knödlseder N; Güell M
    Methods Mol Biol; 2019; 1961():3-11. PubMed ID: 30912036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of genome editing through CRISPR-Cas9 engineering.
    Zhang JH; Adikaram P; Pandey M; Genis A; Simonds WF
    Bioengineered; 2016 Apr; 7(3):166-74. PubMed ID: 27340770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying genome-wide off-target sites of CRISPR RNA-guided nucleases and deaminases with Digenome-seq.
    Kim D; Kang BC; Kim JS
    Nat Protoc; 2021 Feb; 16(2):1170-1192. PubMed ID: 33462439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating and Enhancing Target Specificity of Gene-Editing Nucleases and Deaminases.
    Kim D; Luk K; Wolfe SA; Kim JS
    Annu Rev Biochem; 2019 Jun; 88():191-220. PubMed ID: 30883196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Off- and on-target effects of genome editing in mouse embryos.
    Ayabe S; Nakashima K; Yoshiki A
    J Reprod Dev; 2019 Feb; 65(1):1-5. PubMed ID: 30518723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene Editing in B-Lymphoma Cell Lines Using CRISPR/Cas9 Technology.
    Bai B; Myklebust JH; Wälchli S
    Methods Mol Biol; 2020; 2115():445-454. PubMed ID: 32006416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing.
    Naeem M; Majeed S; Hoque MZ; Ahmad I
    Cells; 2020 Jul; 9(7):. PubMed ID: 32630835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9 Guide RNA Design Rules for Predicting Activity.
    Hiranniramol K; Chen Y; Wang X
    Methods Mol Biol; 2020; 2115():351-364. PubMed ID: 32006410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR-Cas systems: ushering in the new genome editing era.
    Perez Rojo F; Nyman RKM; Johnson AAT; Navarro MP; Ryan MH; Erskine W; Kaur P
    Bioengineered; 2018; 9(1):214-221. PubMed ID: 29968520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR GUARD protects off-target sites from Cas9 nuclease activity using short guide RNAs.
    Coelho MA; De Braekeleer E; Firth M; Bista M; Lukasiak S; Cuomo ME; Taylor BJM
    Nat Commun; 2020 Aug; 11(1):4132. PubMed ID: 32807781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target-Specific Precision of CRISPR-Mediated Genome Editing.
    Chakrabarti AM; Henser-Brownhill T; Monserrat J; Poetsch AR; Luscombe NM; Scaffidi P
    Mol Cell; 2019 Feb; 73(4):699-713.e6. PubMed ID: 30554945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR-Cas9 Genome Editing in Human Cell Lines with Donor Vector Made by Gibson Assembly.
    Sahoo N; Cuello V; Udawant S; Litif C; Mustard JA; Keniry M
    Methods Mol Biol; 2020; 2115():365-383. PubMed ID: 32006411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimizing off-target effects in CRISPR-Cas9 genome editing.
    Chen SJ
    Cell Biol Toxicol; 2019 Oct; 35(5):399-401. PubMed ID: 31317359
    [No Abstract]   [Full Text] [Related]  

  • 19. Battling CRISPR-Cas9 off-target genome editing.
    Li D; Zhou H; Zeng X
    Cell Biol Toxicol; 2019 Oct; 35(5):403-406. PubMed ID: 31313008
    [No Abstract]   [Full Text] [Related]  

  • 20. Computational Analysis Concerning the Impact of DNA Accessibility on CRISPR-Cas9 Cleavage Efficiency.
    Chung CH; Allen AG; Sullivan NT; Atkins A; Nonnemacher MR; Wigdahl B; Dampier W
    Mol Ther; 2020 Jan; 28(1):19-28. PubMed ID: 31672284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.